Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study - Takeaways - MDSpire

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • By

  • Andrew Blauvelt

  • H. Chih-Ho Hong

  • Norito Katoh

  • Richard G. Langley

  • Vivian Laquer

  • Aleksandra Lesiak

  • Ketty Peris

  • Julien Seneschal

  • Juan-Francisco Silvestre

  • Richard B. Warren

  • Andreas Wollenberg

  • Matthew Zirwas

  • Niels Højsager Bennike

  • Farzaneh Safavimanesh

  • Ann-Marie Tindberg

  • Kristian Reich

  • February 5, 2026

  • 0 min

Share

  • 1

    Tralokinumab demonstrated long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis over a 6-year treatment period.

  • 2

    The study included patients aged 12 years and older, treated with tralokinumab for up to 6 years, following completion of parent trials.

  • 3

    No new safety signals were identified, and the long-term safety profile was consistent with previously known data on tralokinumab.

  • 4

    Patients maintained disease control, with significant improvements in various efficacy endpoints throughout the treatment duration.

  • 5

    The findings support the favorable benefit-to-risk profile of tralokinumab for long-term management of atopic dermatitis.

Original Source(s)

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • by Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich

  • February 5, 2026

Related Content

Medical Oddities: Muscle Memory Before Birth? 

When dad trains offspring gain, bar tricks can end in the OR, guts that linger, empathetic pain, and “natural” immune traps this week.

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis

Analysis of Health Claims Data for German Patients with Atopic Dermatitis Not Adequately Managed by Standard Systemic Treatments